Of interest, a recent large prospective study of patients progressing under abiraterone acetate/enzalutamide underlined that different tumor features, such as neuroendocrine markers, loss of the retinoblastoma susceptibility gene (RB1), small cell histology, and AR expression modulation, have only partial connections [80]. The gene discussed is AR; the disease is neoplasm.